<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245800</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008861</org_study_id>
    <nct_id>NCT04245800</nct_id>
  </id_info>
  <brief_title>Home Testing of Respiratory Illness</brief_title>
  <official_title>Behavioral Patterns and Patient Self-completed Diagnostic Testing Study of Respiratory Viral Infection &quot;Home Testing of Respiratory Illness&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evidation Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Audere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Evidation Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this research study is to use data from activity trackers (such as Fitbits),
      lab tests, and surveys to see if activity, sleep, and heart rate data can tell the difference
      between when someone has a respiratory illness (e.g., flu) and when they are feeling healthy.
      The research will also study an investigational flu@home test and app. If successful, results
      from the study could be used in the future to better identify people with respiratory
      illness. In addition, this study will test the accuracy of an at-home flu test kit compared
      to laboratory test results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Rationale

      Acute respiratory infections (ARI) cause considerable disease burden globally and can affect
      both the upper and lower respiratory tract. A majority of ARI are caused by viruses, like the
      influenza virus, while bacteria are only implicated in approximately 10% of cases . The
      symptomology across various viral ARI are broadly similar, but two viruses, namely influenza
      and respiratory syncytial virus (RSV) are associated with considerable morbidity and
      mortality among adults and children. More immediate virus identification would improve
      patient health management by triaging appropriate and timely treatment and infection-control
      measures to mitigate health costs, additional health complications, and total days of symptom
      expression.

      Despite viral infections causing the majority of ARIs, 61% of those with acute respiratory
      symptoms receive an antibiotic treatment. Due to the rise of antibiotic resistance, the
      inappropriate and over-prescription of antibiotics has become a severe health risk and is
      contributing to greater health complications and increased mortality rates. As a result, the
      correct diagnosis of the various infections associated with ARIs has become even more
      imperative to not cause undue harm. The abundance, accessibility, and rapidly advancing
      technology in wearable devices contributes to the progress some studies have demonstrated in
      using the devices as a potential mechanism to more rapidly identify various diseases. Though
      limited research has explored this new perspective specifically in illnesses associated with
      ARI, recent findings were able to demonstrate influenza signals at a population level using
      step, sleep, and heart rate data collected from consumer wearable devices.

      Influenza virus is important to diagnose correctly because, despite annual vaccinations, it
      has been associated with higher morbidity and mortality than most other ARI viruses and has
      been associated with greater individual symptom severity. During the 2017-2018 flu season in
      the United States, it was estimated that 48.8 million people became sick with influenza,
      959,000 were hospitalized, and there were 79,400 deaths recorded due to influenza.
      Additionally, more vulnerable populations, like young children, those experiencing chronic
      illness, and older adults, disproportionately represent the hospitalization and death totals
      reported. Older adults represented 70% of influenza related hospitalizations in the 2017-2018
      flu season and 90% of influenza related deaths.

      The rapid diagnosis of influenza is also of particular importance due to the effectiveness of
      influenza antiviral medication that is largely limited to initiation within 48 hours of
      symptom onset. Additionally, rapid diagnosis also has the potential to enact infection
      control measures to attenuate viral spread, particularly among vulnerable populations, using
      behavioral interventions or other non-pharmaceutical approaches. Diagnosis of influenza
      infection in centralized laboratories has largely progressed from traditional viral culture
      to the use of reverse transcription-polymerase chain reaction (RT-PCR) methods .
      Alternatively, influenza infection can be detected within a medical office or pharmacy using
      commercially-available rapid diagnostic tests (RDTs) of varying complexity, cost and
      accuracy.

      There is now interest to expand RDTs to self-conducted tests that individuals can complete at
      home to further reduce the period between the onset of illness and effective treatment.
      Audere, a digital health non-profit, developed a mobile device app, the flu@home app, to
      guide individuals to perform an influenza RDT themselves without being in a clinical setting.
      The flu@home test uses a mixture of images and written directions prompted through the
      flu@home app to walk individuals through an influenza RDT process. The flu@home test also
      includes modified influenza RDT test material from an FDA 510(k) cleared RDT and includes an
      optional in-app automated influenza RDT test result interpretation system to eventually help
      inform health decisions and behaviors. Though no research has been published on the efficacy
      of the flu@home system, it has been implemented, and is being investigated, in two large
      prospective observational clinical studies during the 2019-2020 flu season, with
      collaborators at the University of Washington, Seattle and University of Adelaide, Australia.

      Expanding on the previous research and development that has been done, the aim of this study
      is to develop a methodology to better classify and detect RVI cases, including influenza,
      through the use of behavioral data and patient-reported outcomes, using RVI confirmation
      through laboratory testing as a reference. This study also aims to assess the accuracy of the
      flu@home RDT self-test, the in-app automated RDT test result interpretation, and a data
      enhanced RDT test interpretation, compared to the interpretation provided by a trained
      professional RDT reader, the PCR test result, and a reference influenza test
      interpretations/analysis.

      Device Description

      The flu@home test kit is an at-home self-administered modified influenza RDT that is
      completed with the assistance of a mobile device app. The flu@home app feature was developed
      by Audere, a digital health non-profit based in Seattle. The flu@home test consists of the
      instructional app experience that guides participants through the influenza RDT procedure and
      the physical material of the RDT influenza test kit modified from the Quidel QuickVue
      Influenza A+B test. The flu@home app will solely be utilized as an instructional guide and
      research data collection tool for this study.

      The flu@home test kit's instructional app features are available on iOS and Android
      platforms. The instructional app features include multiple pages of text and imagery content
      guiding participants through the entirety of the influenza RDT process, from completing a
      nasal swab to adding solution into a test tube to run a lateral flow immunoassay. The
      instructional app also includes an in-app questionnaire for participants to complete during a
      10-minute participant wait period while their immunoassay processes. The flu@home test kit
      also guides participants through the viral collection and appropriate transport procedure of
      study samples for additional RVI analysis to be completed at an accredited laboratory.

      The physical material of the flu@home test kit consists of components from an existing
      commercial influenza RDT, with additional material to collect and return a reference sample
      for laboratory testing. The complete flu@home test kit includes two foam-tipped nasal swabs,
      a small tube with dried reagent, a saline vial, a lateral-flow immunoassay test strip, and a
      tube with liquid reagent for the PCR test. RDT testing material is utilized from the
      CLIA-waived Quidel QuickVue Influenza A+B Test. All physical testing material will be
      assembled and mailed to participants through a 3rd party vendor, Molecular Testing Lab (MTL).
      The flu@home test kit also includes mailing material for participants to return the RDT test
      remnant and strip to be discarded by MTL and the reference nasal swab for laboratory testing
      through PCR procedures at MTL's accredited facility.

      The flu@home test kit's interpretation features will not be shared with participants within
      the parameters of this study.

      Regulatory Status

      The flu@home test kit is considered a non-significant investigational device that is being
      used for data collection purposes and will be labeled as an investigational device. The test
      kit contains foam-tipped nasal swabs, a small tube with dried reagent, a saline vial and test
      strip from the CLIA-waived Quidel QuickVue Influenza A+B Test, and a tube with liquid reagent
      for the PCR test.

      Explanation of choice comparator

      PCR (RT-PCR for RNA viruses including influenza) is a reliable reference test for influenza
      and other respiratory viruses. RT-PCR was identified as the comparator for the modified
      at-home self-administered influenza RDT. Though RDTs can produce results in a much shorter
      period of time than RT-PCRs, RT-PCRs have been found to have more sensitivity to the
      influenza viruses than do RDTs. PCR or RT-PCR is often used as the reference test in research
      studies and studies designed for FDA submission (e.g., influenza RT-PCR was used as a
      reference test in the FDA 510(k) submission for the Quidel QuickVue Influenza A+B Test;
      Quidel, 2018).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Actual">July 6, 2020</completion_date>
  <primary_completion_date type="Actual">July 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of RVI cases through the use of behavioral data and patient-reported outcomes</measure>
    <time_frame>End of month 4 (when data collection concludes)</time_frame>
    <description>Behavioral data from Fitbit wearables, patient self-reported data (includes but is not limited to demographics, symptoms, medical history, lifestyle, comorbidities, and Medical care utilization), and diagnostics during flu or RVI episode</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Database development of Influenza and/or other RVI confirmations collected during the 2019-2020 flu season.</measure>
    <time_frame>End of month 4 (when data collection concludes)</time_frame>
    <description>Behavioral data from Fitbit wearables, patient self-reported data (includes but is not limited to demographics, symptoms, medical history, lifestyle, comorbidities, and Medical care utilization), and diagnostics during flu or RVI episode</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Built, trained and tested analytical model for future real-time RVI surveillance systems</measure>
    <time_frame>End of month 4 (when data collection concludes)</time_frame>
    <description>Database comprised of behavioral data from Fitbit wearables, patient self-reported data (includes but is not limited to demographics, symptoms, medical history, lifestyle, comorbidities, and Medical care utilization), and diagnostics during flu or RVI episode</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative accuracy of flu@home RDT</measure>
    <time_frame>End of month 4 (when data collection concludes)</time_frame>
    <description>Comparative accuracy of the flu@home RDT self-test, the in-app automated RDT test result interpretation, and a data enhanced RDT test interpretation, compared to the interpretation provided by a trained professional RDT reader, the PCR test result, and reference influenza test interpretations/analysis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5233</enrollment>
  <condition>Influenza -Like Illness</condition>
  <condition>Influenza A</condition>
  <condition>Influenza Type B</condition>
  <condition>Respiratory Viral Infection</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>All participants will be part of the prospective observational cohort. If participants develop flu-like symptoms, they will be prompted to complete the flu@home self-test kit. Analysis will be conducted for various subgroups (e.g. age, vaccination status)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants will collect a low nasal swab for PCR testing. The nasal swab will be mailed to
      a partner laboratory facility where the sample will be tested through PCR procedures for
      various RVIs. Immediate analysis will be done to identify iInfluenza A, influenza B, and
      respiratory syncytial virus (RSV). Samples will then be frozen, after which additional
      testing may be conducted to identify the presence of respiratory pathogens including
      adenovirus, coronavirus, human metapneumovirus, rhinovirus, and parainfluenza virus. No
      influenza or other RVI test results will be communicated back to the participant during their
      time in the study.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults living in the US
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Lives in the United States

          -  Speaks, reads, and understands English

          -  Owns a wearable Fitbit that collects heart rate data

          -  Willing to connect their Fitbit to the Achievement study platform and wear their
             Fitbit daily during the day and during sleep for the duration of the study

          -  Willing to respond to short daily questionnaires for a 4-month period

          -  Has an iOS or Android smartphone or tablet that is capable of supporting the Audere
             flu@home app

          -  Google Play Store compatible Android devices on Android 5.1 or later

          -  iOS devices on iOS 11 or later

          -  Willing to download the flu@home app

          -  Willing to complete an at-home flu test kit (via two nasal swabs) and return the nasal
             swab samples within 24 hours of being asked to complete a flu test kit

        Exclusion Criteria:

          -  Diagnosed with flu by a healthcare professional in the past 3 months

          -  Currently enrolled in another flu study being conducted by Evidation
             Health/Achievement Studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Thompson, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessie L Juusola, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evidation Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernesto Ramirez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Evidation Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry Lutz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washinton</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evidation Health</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.quidel.com/sites/default/files/product/documents/EF1350313EN00_1.pdf</url>
    <description>CLIA Waiver for Quidel QuickVue Influenza A + B Test. (Part of flu@home kit)</description>
  </link>
  <link>
    <url>https://www.cdc.gov/flu/about/burden/index.html</url>
    <description>Disease burden of Influenza</description>
  </link>
  <reference>
    <citation>Abu-Diab A, Azzeh M, Ghneim R, Ghneim R, Zoughbi M, Turkuman S, Rishmawi N, Issa AE, Siriani I, Dauodi R, Kattan R, Hindiyeh MY. Comparison between pernasal flocked swabs and nasopharyngeal aspirates for detection of common respiratory viruses in samples from children. J Clin Microbiol. 2008 Jul;46(7):2414-7. doi: 10.1128/JCM.00369-08. Epub 2008 May 14.</citation>
    <PMID>18480225</PMID>
  </reference>
  <reference>
    <citation>Bradshaw B, Konty KJ, Ramirez E, et al. 2019. Influenza surveillance using wearable mobile health devices, Online J Public Health Inform, 11:e249</citation>
  </reference>
  <reference>
    <citation>Burnham JP, Olsen MA, Kollef MH. Re-estimating annual deaths due to multidrug-resistant organism infections. Infect Control Hosp Epidemiol. 2019 Jan;40(1):112-113. doi: 10.1017/ice.2018.304. Epub 2018 Nov 22.</citation>
    <PMID>30463634</PMID>
  </reference>
  <reference>
    <citation>Donnelly JP, Baddley JW, Wang HE. Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments. Antimicrob Agents Chemother. 2014;58(3):1451-7. doi: 10.1128/AAC.02039-13. Epub 2013 Dec 16.</citation>
    <PMID>24342652</PMID>
  </reference>
  <reference>
    <citation>Durkin MJ, Jafarzadeh SR, Hsueh K, Sallah YH, Munshi KD, Henderson RR, Fraser VJ. Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study. Infect Control Hosp Epidemiol. 2018 May;39(5):584-589. doi: 10.1017/ice.2018.26. Epub 2018 Feb 27.</citation>
    <PMID>29485018</PMID>
  </reference>
  <reference>
    <citation>DziÄ…bowska K, Czaczyk E, Nidzworski D. Detection Methods of Human and Animal Influenza Virus-Current Trends. Biosensors (Basel). 2018 Oct 18;8(4). pii: E94. doi: 10.3390/bios8040094. Review.</citation>
    <PMID>30340339</PMID>
  </reference>
  <reference>
    <citation>Ebell MH, Afonso A. A systematic review of clinical decision rules for the diagnosis of influenza. Ann Fam Med. 2011 Jan-Feb;9(1):69-77. doi: 10.1370/afm.1192. Review.</citation>
    <PMID>21242564</PMID>
  </reference>
  <reference>
    <citation>Ebell MH, Afonso AM, Gonzales R, Stein J, Genton B, Senn N. Development and validation of a clinical decision rule for the diagnosis of influenza. J Am Board Fam Med. 2012 Jan-Feb;25(1):55-62. doi: 10.3122/jabfm.2012.01.110161.</citation>
    <PMID>22218625</PMID>
  </reference>
  <reference>
    <citation>Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003 Feb 24;163(4):487-94.</citation>
    <PMID>12588210</PMID>
  </reference>
  <reference>
    <citation>Kwon YS, Park SH, Kim MA, Kim HJ, Park JS, Lee MY, Lee CW, Dauti S, Choi WI. Risk of mortality associated with respiratory syncytial virus and influenza infection in adults. BMC Infect Dis. 2017 Dec 20;17(1):785. doi: 10.1186/s12879-017-2897-4.</citation>
    <PMID>29262784</PMID>
  </reference>
  <reference>
    <citation>Larios OE, Coleman BL, Drews SJ, Mazzulli T, Borgundvaag B, Green K; STOP-Flu Study Group, McGeer AJ. Self-collected mid-turbinate swabs for the detection of respiratory viruses in adults with acute respiratory illnesses. PLoS One. 2011;6(6):e21335. doi: 10.1371/journal.pone.0021335. Epub 2011 Jun 23.</citation>
    <PMID>21731708</PMID>
  </reference>
  <reference>
    <citation>Pope LE, Hobbs CG. Epistaxis: an update on current management. Postgrad Med J. 2005 May;81(955):309-14. Review.</citation>
    <PMID>15879044</PMID>
  </reference>
  <reference>
    <citation>Ross MH, Zick BL, Tsalik EL. Host-Based Diagnostics for Acute Respiratory Infections. Clin Ther. 2019 Oct;41(10):1923-1938. doi: 10.1016/j.clinthera.2019.06.007. Epub 2019 Jul 26. Review.</citation>
    <PMID>31353133</PMID>
  </reference>
  <reference>
    <citation>Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. JAMA. 2016 Nov 22;316(20):2115-2125. doi: 10.1001/jama.2016.16201.</citation>
    <PMID>27893129</PMID>
  </reference>
  <reference>
    <citation>Smith SM, Sonego S, Wallen GR, Waterer G, Cheng AC, Thompson P. Use of non-pharmaceutical interventions to reduce the transmission of influenza in adults: A systematic review. Respirology. 2015 Aug;20(6):896-903. doi: 10.1111/resp.12541. Epub 2015 Apr 14. Review.</citation>
    <PMID>25873071</PMID>
  </reference>
  <reference>
    <citation>Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902. doi: 10.1093/cid/ciy874.</citation>
    <PMID>30834445</PMID>
  </reference>
  <reference>
    <citation>VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infect Dis. 2014 May 1;14:231. doi: 10.1186/1471-2334-14-231.</citation>
    <PMID>24884932</PMID>
  </reference>
  <reference>
    <citation>Vos LM, Bruning AHL, Reitsma JB, Schuurman R, Riezebos-Brilman A, Hoepelman AIM, Oosterheert JJ. Rapid Molecular Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review of Diagnostic Accuracy and Clinical Impact Studies. Clin Infect Dis. 2019 Sep 13;69(7):1243-1253. doi: 10.1093/cid/ciz056.</citation>
    <PMID>30689772</PMID>
  </reference>
  <reference>
    <citation>Walker TA, Khurana S, Tilden SJ. Viral respiratory infections. Pediatr Clin North Am. 1994 Dec;41(6):1365-81. Review. Erratum in: Pediatr Clin North Am 1995 Apr;42(4):xi.</citation>
    <PMID>7984389</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Evidation Health</investigator_affiliation>
    <investigator_full_name>Jessie Juusola</investigator_full_name>
    <investigator_title>Sr Director, Health Outcomes Research</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>self-testing</keyword>
  <keyword>diagnostic accuracy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Coded Study Data may also be transferred to external research partners in accordance with IRB approved uses. Coded Study Data consists of all data collected within the parameters of this study, excluding any identifying information. After completion of the study, any potentially identifiable information will be removed and Coded Study Data will be made available to qualified researchers using the Synapse Platform run by Sage Bionetworks, a US-based non-profit focused on furthering scientific knowledge.</ipd_description>
    <ipd_time_frame>At the end of month 4 (when data collection concludes)</ipd_time_frame>
    <ipd_access_criteria>Coded Study Data will be accessible by qualified researchers registered with the Synapse platform. The Synapse platform has rules to qualify researchers, and qualified researchers must register on Synapse, confirm their identity, and write a short statement about their research. The research could be about any topic. Researchers must sign an oath to use the data ethically and do no harm.</ipd_access_criteria>
    <ipd_url>https://docs.synapse.org/articles/governance.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

